Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.
Front Immunol
; 6: 593, 2015.
Article
en En
| MEDLINE
| ID: mdl-26635807
ABSTRACT
T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Front Immunol
Año:
2015
Tipo del documento:
Article
País de afiliación:
Italia